Author of

• 12727

  +

  P3.13 - Poster Session 3 - SCLC (ID 202)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12731

    +

    P3.13-004 - A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer (ID 1335)

    09:30 - 09:30  |  Author(s): C.D. Yeo
    • Abstract

    Background
    Belotecan is a new camptothecin analogue and a potent topoisomerase I inhibitor. The aim of this phase II study was to investigate the efficacy and toxicity of belotecan in previously untreated elderly patients with small cell lung cancer (SCLC).

    Methods
    A total of 26 patients, aged ≥65 years, with previously untreated, extensive-stage SCLC were enrolled in the study. Belotecan was administered by daily intravenous infusion at 0.5 mg/m[2]/day for 5 consecutive days every three weeks.

    Results
    The overall response rate and disease control rate of chemotherapy on an intention-to-treat basis were 35% and 54%, respectively. The median overall survival was 6.4 months, and the median time to progression was 2.8 months. The most common toxicity was hematologic. Grade 3 or 4 neutropenia occurred in 80.8% of patients, and grade 3 or 4 thrombocytopenia in 15.3%. Non-hematologic toxic effects of grade 3 or 4 were uncommon.

    Conclusion
    Belotecan had modest efficacy and well-tolerated toxicity in previously untreated, elderly SCLC patients. Single belotecan could be a promising treatment option, considering its lower toxicity in elderly patients who are unsuitable candidates for platinum plus etoposide chemotherapy.